| Objective To evaluate the clinical curative effect of allo-HSCT forAL.Methods Twenty-eight patients with acute leukemia [7cases withacute lymphoblastic leukemia (ALL),21cases with acute myeloidleukemia (AML)] received the treatment of allo-HSCT with HLA matchedsibling donors except two cases (5/6matched) in our hospital from January2005to August2011. Twenty-two patients were pre-conditioned withBu/Cy regimen,3patients with modified Bu/Cy regimen,3patients withfludarabine(Flu)/Bu/Cy regimen. The routine prevention of GVHDconsisted of MTX and CsA.Results28patients after transplantation were quickly achievedhematopoietic and immune function reconstitution after allo-HSCT. Themedian follow-up duration was22months. At the end of follow-up, overallsurvival (OS) was71.4%, among them,16patients (57.1%) survived withdisease-free survival (DFS) in11to79months after allo-HSCT. There wasno acute graft-versus-host disease presented,6patients had cGVHD. Eightpatients were respectively died of cGVHD, relapse or progression of infection and disease after transplantation. The patients who had CR1achieved higher overall survival rate and disease-free survival rate aftertransplantation than those who had CR2or NR patients during the sameperiod.Conclusions Allo-HSCT is a safe and effective method fortreatment of AL；the patients should adopt allo-HSCT as soon as possibleafter the CR1. |
PDF Full Text Request